Zeleciment basivarsen not checked
Dyne Therapeutics · DYNE-101
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Myotonic Dystrophy Type 1 (DM1) (2 trials), DM1, Myotonic Dystrophy, Steinert Disease, Steinert
- Main trialPhase 3
- “The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).”In the company’s words, NCT07486934 on ClinicalTrials.gov
- Other names
- DYNE-101
Other drugs for Myotonic Dystrophy Type 1 (DM1)
- TideglusibAMO Pharma Limited · Phase 2/3
- Mexiletine granulesLupin Ltd. · Phase 3
- AOC 1044Avidity Biosciences, Inc. · Phase 3
- Del-desiranAvidity Biosciences, Inc. · Phase 3
- Zeleciment RostudirsenDyne Therapeutics · Phase 3
- SRP-1003Sarepta Therapeutics, Inc. · Phase 1/2
Coming up2
- Jul 2028Phase 3 trial completes · ClinicalTrials.gov
- Jul 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jul 2028 | Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 | |
| Phase 1/2Active, not recruiting | Jul 2029 | Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026